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RESUMO 
 
O herpesvírus murídeo do tipo 4, MuHV-4, é um gama-herpesvirus capaz de 
estabelecer infecções latentes em tecidos linfóides. Tal como outros herpesvírus, o 
MuHV-4 possui duas fases de expressão génica - a lítica e a latente – o que lhe 
permite estabelecer infecções crónicas durante toda a vida do hospedeiro. Durante a 
latência, o genoma de MuHV-4 persiste no núcleo de células latentemente infectadas 
sob a forma de epissoma, não havendo produção de viriões. MuHV-4 estabelece 
latência maioritariamente em células B que se encontram em proliferação em centros 
germinais, que por sua vez dão acesso às células B de memória de longa duração.  
Durante a infecção latente, o MuHV-4 expressa a proteína mLANA que se liga 
aos elementos repetitivos do genoma do vírus e aos cromossomas mitóticos do 
hospedeiro, permitindo a segregação do epissoma em células em divisão. Além do 
seu papel fundamental na manutenção do epissoma viral, mLANA é também uma 
proteína reguladora da transcrição, modulando substratos celulares, tais como NF-kB 
e MYC, sendo este último necessário para o desenvolvimento e manutenção de 
centros germinais. O mecanismo envolve a formação do complexo de ligase de 
ubiquitina EC5S mediado por um motivo SOCS-box-like presente em mLANA. O 
complexo EC5SmLANA interage com RelA, um dos membros da família NF-kB, 
promovendo a sua poli-ubiquitinação e consequente degradação pelo proteossoma. O 
complexo EC5SmLANA também promove a poli-ubiquitinação de MYC mas 
contrariamente ao que acontece com NF-kB que é degradado, MYC é estabilizado 
durante o ciclo celular, levando a uma linfoproliferação. Deste modo, mLANA tem 
efeitos antagónicos sobre os dois factores de transcrição - inibe a actividade 
transcricional de NF-Kb mas activa a actividade transcricional de MYC. Portanto, ao 
sequestrar o controlo pós- transcricional de MYC, mLANA aumenta o número de 
células B infectadas nos centros germinais. 
Numa tentativa, por parte de investigadores do nosso laboratório, para localizar 
a região de mLANA responsável pela interacção com os alvos, foi construída uma 
série de mutantes com delecções ao longo de mLANA. Embora o mapeamento tenha 
sido inconclusivo, o mutante D2 demonstrou aumentar a actividade E3 ligase de 
ubiquitina de mLANA resultando na estabilização de MYC e degradação proteossomal 
de NF-kB. 
Em consequência do resultado supramencionado, o objectivo deste projecto foi 
definido: investigar o papel oncogénico da modulação de MYC durante a infecção por 
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gamma-herpesvirus. Para tal, dois vírus MuHV-4 recombinantes foram construídos, 
vD2 com uma delecção (Δ11-20) em mLANA que aumenta o efeito modulatório sobre 
MYC e vD2L92A que combina a mutação anterior com uma mutação em M2, uma 
proteína que se localiza predominantemente no citoplasma e membrana celular de 
células infectadas, e que possui um epítopo de células T restrito a H2-kd que, sabe-se 
que induz uma linfoproliferação persistente em centros germinais. A construção dos 
vírus recombinantes foi feita através da mutagénese de BAC. Esta técnica permite a 
manutenção do genoma viral como BAC em E. coli e mutagénese do genoma através 
de recombinação homóloga. A confirmação da integridade das mutações em mLANA 
foi feita através de sequenciação ao longo da região mutada. A estabilidade do 
genoma viral clonado como plasmídeo BAC foi confirmada por digestão com as 
enzimas de restrição EcoRI e BamHI e os seus perfis de restrição foram comparados 
com os do MuHV-4 BAC. Após a identificação de BACs recombinantes, reconstruíram-
se os vírus recombinantes em BHK-21 com posterior passagem por células NIH Cre 
3T3 de forma a extrair as sequências BAC. Foi demonstrado que estas últimas 
sequências podem atenuar o crescimento dos vírus in vivo.  
Para a produção de stocks virais, infectaram-se células BHK-21 com uma 
multiplicidade de infecção baixa de forma a não se produzirem vírus defectivos e os 
seus títulos foram determinados através de um ensaio de suspensão. Este ensaio 
consiste em diluições seriadas das suspensões virais com posterior adição de um 
número conhecido de células permissivas, células BHK-21. Após um período de 
incubação de 4 dias os títulos são calculados através da contagem de unidades 
formadoras de placas e tendo em conta o número de células permissivas adicionado.  
Seguidamente foi avaliada a cinética da replicação viral dos vírus 
recombinantes através de curvas de crescimento multistep. Ambos os vírus 
demonstraram uma cinética semelhante à do vírus MuHV-4, demonstrando que as 
mutações introduzidas não afectaram a replicação lítica in vitro. 
Os efeitos na fase latente de infecção das mutações introduzidas foram 
testados com um ensaio de reactivação ex vivo, em que ratinhos BALB/c foram 
infectados intranasalmente com MuHV-4 e as versões recombinantes. O ensaio 
consiste numa co-cultura de suspensões unicelulares provenientes de baços de 
animais infectados com fibroblastos permissíveis. A presença de vírus latentes na 
população inicial de esplenócitos resulta num efeito citopático nas camadas de 
fibroblastos e, a não ser que vírus infecciosos estejam presentes na altura da recolha 
dos baços, o efeito citopático é somente resultado da reactivação de vírus latentes. A 
capacidade de estabelecer e expandir uma infecção latente no baço foi avaliada aos 
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dias 14, 21 e 50 pós-infecção. Tanto vD2 como vD2L92A demonstraram um severo 
deficit no estabelecimento e manutenção de uma infecção latente. Enquanto animais 
infectados com o vírus D2 ainda exibiram uma dose latente baixa, com vírus latentes 
um pouco acima do limite de detecção, os vírus latentes D2L92A estiveram sempre 
abaixo do nível de detecção. 
A proteína mLANA possui um sinal de localização nuclear putativo e, embora a 
mutação mLANA-D2 não tenho sido nesse local, pode ter modificado a estrutura da 
proteína e impedido a sua localização nuclear. Para tal, realizou-se uma 
imunofluorescência em células A20 transfectadas com plasmídeos mLANA-D2-GFP. 
Os resultados demonstraram que mLANA-D2 localiza-se no núcleo em células 
transfectadas. 
A capacidade de expressão dos mutantes de mLANA também foi avaliada, 
através de experiências de immunoblotting. Para tal infectaram-se células BHK-21 
com o vírus WT e as versões recombinantes e os resultados revelaram que ambos os 
vírus, vD2 e vD2L92A expressavam mLANA equivalentemente e que o fenótipo do 
ensaio de reactivação ex vivo não foi devido à falta da expressão da proteína viral. 
O facto de os vírus recombinantes de MuHV-4 não conseguirem estabelecer e 
manter uma infecção latente, demonstra que as mutações introduzidas não são ideais 
para induzir linfoproliferação em centros germinais e desse modo obter um modelo de 
estudo para o desenvolvimento de alvos terapêuticos para doenças associadas a 
gamma-herpesvirus. Assim, é necessário desenvolver novas estratégias para a 
construção de vírus recombinantes capazes de manter uma infecção latente 
persistente. 
Contudo, também seria interessante desenvolver estratégias de forma a 
descortinar a razão pela qual ambos os vírus recombinantes demonstraram um défice 
muito acentuado no estabelecimento e manutenção da latência. A razão pode ser 
devida à incapacidade da mLANA mutada em manter o seu papel putativo na 
manutenção do epissoma. A resolução deste problema pode contribuir grandemente 
para actuar sobre doenças crónicas causadas por gamma-herpesvirus. 
 
 
Palavras-chave: mLANA, NF-Kb, MYC, ensaio de reactivação ex vivo, défice de 
latência. 
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ABSTRACT 
 
Murid herpesvirus-4 (MuHV-4) is a gamma-2-herpesvirus capable of 
establishing latent infections in lymphoid tissues. During latency, MuHV-4 expresses 
mLANA, which mediates episome persistence, tethering viral genome to mitotic host 
chromosomes. Moreover, mLANA has been implicated in the modulation of the cellular 
transcription factors NF-kB and MYC by assembling and EC5CmLANA ubiquitin-ligase 
complex. EC5CmLANA targets NF-kB family member RelA for poly-ubiquitination and 
subsequent proteosomal degradation. EC5CmLANA also mediates MYC poly-
ubiquitination but this leads to its turnover and stability. Thus, mLANA by increasing 
MYC stability through the cell cycle, subsequently potentiates lymphoproliferation and 
disease. 
The aim of this project was to investigate the oncogenic role of MYC modulation 
during gammaherpesvirus infection. To this end, two recombinant MuHV-4 viruses 
were constructed: vD2 with mutations in mLANA that increase the modulation effect on 
MYC, and vD2L92A combining the previous mutation with a mutation in H2- kd-
restricted T cell epitope which induce persistent lymphoproliferation in germinal 
centres. Recombinant viruses were engineered by mutagenesis of the viral genome 
cloned as a BAC and tested on their capacity to establish and expand a latent load in 
the spleen and their ability to maintain a long-term persistence. Both recombinant 
viruses displayed a major deficit in splenic latency, incapable of establishing and 
maintaining a latent infection. The introduced delection in mLANA did not affected its 
nuclear localization as well its expression as it was assessed by immunofluoresce 
assay and immunoblotting, respectively. These results suggested that the mutations in 
mLANA somehow rendered recombinant viruses inaptitude to attach to host 
chromosomes and thus maintain a latent infection.  
The overall results showed that vD2 and vD2L92A are not useful to study the 
molecular pathways critical for virus-induced lymphoproliferation. New strategies must 
be developed in order to potentiate tumorigenesis. 
 
 
Keywords: mLANA, NF-Kb, MYC, infectious center assay, latency deficit 
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1. INTRODUCTION 
 
1.1 Herpesviruses 
Herpesviridae family consists of enveloped viruses with large double-stranded 
DNA genomes that range from 120 to 250 kb. This family is ancient and widely 
disseminated in nature with members found in a large spectrum of vertebrate species 
(Barton et al., 2011). Herpesviruses are ubiquitous in the general population and 
remarkably well adapted to their hosts, a characteristic that is probably the result of a 
very long co-evolutionary history (Davison, 2002). Molecular phylogenetic studies 
suggest that herpesviruses speciation occurred at approximately the same time as did 
host speciation. As an outcome of this adaptation, herpesvirus infection of a natural 
immunocompetent host is rarely fatal (Davison, 2002). Herpesviruses have two 
alternative gene expression programs, a lytic and a latent phase, which allow 
herpesvirus to strategically establish life-long persistent infections in hosts. During the 
lytic replication, there is viral gene expression in a highly-ordered manner, being the 
viral genome replicated several times with the production of infectious virion progeny 
and the death of infected cells. Following lytic infection, the latent phase is established 
throughout the life of the host, with limited gene expression and without virion 
production enabling the virus to escape the host immune control (Wu et al., 2010)). 
This phase is characterized by sporadic reactivation episodes which ensure the 
transmission of infectious virions to new hosts as well as reinfection and establishment 
of a latent reservoir of infected cells for life (Cohen et al., 2003). In immunocompetent 
hosts, infections by several herpesvirus are usually asymptomatic or cause mild illness 
but in immunocompromised hosts can lead to fatal consequence (Wu et al., 2010).  
The family Herpesviridae is divided into three subfamilies: Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae (Davison et al., 2009). Alpha-herpesvirus 
are neurotropic, establishing latency mainly in neurons of the sensory ganglia, beta-
herpesvirus are the largest members of the herpesvirus family and are found latent 
preferently in hematopoietic stem cells and in cells of the myeloid lineage. 
Gammaherpesviruses are lymphotropic, establishing latency in B lymphocytes, being 
associated with lymphoid tissue (Davison et al., 2009). Until now, eight human 
herpesviruses have been identified: herpes simplex virus (HSV)-1, HSV-2 and 
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varicella-zoster virus (VZV) (Alphaherpesvirinae); human herpesvirus (HHV)-6 and 
HHV-7 and human cytomegalovirus (HCMV) (Betaherpesvirinae); Epstein-Barr virus 
(EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as HHV-8 
(Wu et al., 2010).  
 
1.1.1 Gammmaherpesviruses 
Gammaherpesviruses are lymphotropic viruses widely spread in nature and 
although they are host-range specific, these viruses have been identified in a variety of 
mammalian species. Members of the gammaherpesvirus subfamily establish latent 
infections in lymphocytes, which can lead to the development of lymphoproliferative 
diseases and lymphomas as well as non-lymphoid cell tumors in immunocompromised 
hosts (Nash et al., 2001). 
This subfamily is divided into two genera: gamma-1-herpesvirus, exemplified by 
Epstein-Barr virus (EBV) (Simas & Efstathiou, 1998) and gamma-2-herpesvirus, 
typified by the Kaposi’s sarcoma-associated herpesvirus (KSHV) (Chang et al., 1994).  
 
1.2 Kaposi’s sarcoma-associated herpesvirus 
Kaposi´s sarcoma-associated herpesvirus (or human herpesvirus 8) is the most 
recently discovered human herpesvirus (Chang et al., 1994) and has an etiologic role 
in Kaposi´s sarcoma as well in primary effusion lymphoma and multicentric 
Castleman’s disease (Chang et al., 1994; Moore & Chang, 2003; Soulier et al., 1995).  
The presence of KSHV in the population is uncommon with approximately 1-5 % in 
North America and Northern Europe. In some Sub-Saharan Africa countries the 
seroprevalence rates exceed 60 % (Moore & Chang, 2003). Despite Kaposi´s sarcoma 
low malignant potential in immunocompetent individuals, because of the AIDS 
epidemic, KS became major contributor to morbidity and mortality in 
immunocompromised individuals (Verma & Robertson, 2003). 
Similarly to other herpesvirus, KSHV employs a broad repertoire of immune 
evasion mechanisms in order to establish a persistent infection within its host. KSHV 
manage to do so by undergoing one of two alternative genetic life-cycle programmes 
after infection of host cells. The latent programme enables the virus to persist in a 
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relatively stable and immunological mode, whereas the lytic programme allows virions 
to be shed and transmitted to new hosts (Coscoy, 2007).  
 
1.2.1 KSHV latency-associated protein (kLANA) 
During the latent programme, KSHV genome persists as a multicopy, non-
integrated, circular episome (Decker et al., 1996). This is accomplished by the 
expression of KSHV latency-associated nuclear antigen (kLANA or ORF73) which 
mediates the maintenance of the viral episome in the nucleus (Ballestas et al., 1999). 
kLANA tethers the viral genome to mitotic chromosome, which allows passive 
segregation of viral DNA to daughter nuclei and thus episome persistence in the 
progeny of dividing cells (Ballestas & Kaye, 2001; Garber et al., 2002). The C-terminus 
region of kLANA harbours a DNA-binding domain (DBD) that self-associates and binds 
to terminal repeats (TR) DNA sequences of the viral episome  (Ballestas & Kaye, 2001; 
Schwan et al., 2000 ). The N-terminus region of kLANA is able to attach to 
chromosomes by binding nucleosomes through the folded region of histones H2A-H2B 
(Barbera et al., 2006). Another role for kLANA is in repressing the transcriptional 
activity of Rta, a KSHV immediate-early gene that activates lytic replication, 
maintaining latency (Lan et al., 2004). kLANA can also act like a nuclear regulator of 
gene transcription by interacting with several other cellular proteins thus regulating cell 
survival and growth (Verma et al., 2007).  kLANA manage to do so by inactivating the 
tumor suppressor functions of p53 (Cai et al., 2006) and stabilizing and activating 
oncogene c-Myc (Liu et al., 2007).  
The multiple functions of kLANA are critical for the maintenance and expansion 
of latency by playing several roles, namely viral genome maintenance, immune system 
evasion, controlling the switch between viral latency and lytic replication and promoting 
the survival and proliferation of latently infected cells. 
 
1.3 Murid herpesvirus-4 
Murid herpesvirus-4 (MuHV-4, also referred to as MHV-68) was first isolated 
from bank voles (Clethrionomys glariolus) captured in Slovakia and is a natural 
pathogen of wild rodents (Blaskovic et al., 1980). It readily infects laboratory mice (Mus 
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musculus), representing a tractable model system for studying gammaherpesvirus 
pathogenesis and enabling the assessment of molecular mechanisms involved in virus-
host interaction (Simas & Efstathiou, 1998). MuHV-4 genome consists of 118 kb of 
unique sequence DNA with a G+C content of 46%, flanked by multiple copies of 1, 2 kb 
terminal repeat regions (Efstathiou et al., 1990). It has approximately 80 open reading 
frames (ORFs) which are collinear and homologous of other gammaherpesviruses, 
namely KSHV, and has several genes encoding functionally homologous to cellular 
proteins (Nash et al., 2001; Virgin et al., 1997). These characteristics closely relate 
MuHV-4 to gamma-2-herpesvirus genus, like KSHV (Virgin et al., 1997).  
Similarly to other gamma-2-herpesvirus, MuHV-4 establishes a lifelong chronic 
infection in lymphoid tissues (Sunil-Chandra et al., 1992b), in which its genome persists 
as an episome in latently infected cells. Mice inoculated via the olfactory 
neuroepithelium (Milho et al., 2012) with MuHV-4 establish an acute phase of virus 
replication in the lungs involving infection of alveolar epithelial cells (Stewart et al., 
1998; Sunil-Chandra et al., 1992a) which is resolved within 9 to 12 days post-infection 
(dpi) (Sunil-Chandra et al., 1992b). After the lytic infection, the virus is spread to lymph 
nodes via dentritic cells (DCs) (Gaspar et al., 2011) and reaches the spleen by 
infecting marginal zone (MZ) macrophages which then pass it to MZ B cells  (Frederico 
et al., 2014). 
The peak of latency is accompanied by a transient splenomegaly (Sunil-
Chandra et al., 1992a) with the levels of latently infected cells decreasing thereafter but 
remaining steady (Cardin et al., 1996; Simas & Efstathiou, 1998). Although other cell 
types have been implicated in latency – alveolar epithelial cells, dendritic cells and 
macrophages – MZ B cells appear to be the main route in which MuHV-4 establishes 
latency in B cells that are proliferating in a germinal centre (GC), which in turn give 
access to the virus to the long-lived memory B cell pool (Frederico et al., 2014; 
Marques et al., 2003). With an equal contribution, these populations of cells have key 
roles in both in the establishment and maintenance of viral latency (Flaño et al., 2002). 
Human gammaherpesviruses, such as EBV and KSHV, do not infect a suitable 
laboratory animal, since they are species-specific viruses. The result is that several 
aspects of their in vivo pathogenesis have remained unknown. With the discovery of 
MuHV-4 infecting mice, a tractable model system to investigate gammaherpesvirus has 
arisen, offering a unique opportunity to investigate immunological and virological 
aspects of gammaherpesvirus pathogenesis (Simas & Efstathiou, 1998). 
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1.3.1 MuHV-4 latency-associated protein (mLANA) 
Similarly to KSHV, MuHV-4 encodes a latency-associated protein, a product of 
ORF73 gene. ORF73 protein (or mLANA) has 314 amino acid residues and has 
substantial homology in sequence and function to ORF73 protein of KSHV (Grundhoff 
& Ganem, 2003). Previous studies have shown that mLANA is required both in vitro 
(Habison et al., 2012) and in vivo (Fowler et al., 2003) for the establishment and 
maintenance of latency. 
 The crucial role of this protein was evidenced when mice infected with 
recombinant virus with mLANA disrupted could not establish splenic latency (Fowler et 
al., 2003). In a mouse model of infection, mLANA is selectively expressed in infected 
GC B cells (Marques et al., 2003). Similarly to KSHV LANA, mLANA was recently 
shown to act on terminal repeat (TR) elements of the MuHV-4 genome to mediate 
episome persistence, tethering viral episome to mitotic host chromossomes allowing 
episome segregation to daughter nuclei during cellular division (Habison et al., 2012). 
The C-terminal region of mLANA, comprising amino acid residues 140 to 263, has 
amino acid similarity to the kLANA DNA-binding domain (Correia et al., 2013). 
Like KSHV LANA, mLANA is also a regulator of transcription. Rodrigues et al. 
have demonstrated that MuHV-4 LANA promotes poly-ubiquitination of cellular 
substrates, NF-kB and MYC, by interfering with their turnover, thus modulating their 
cellular transcription (Rodrigues et al., 2009; Rodrigues et al., 2013). 
All this similar characteristics with KSHV LANA, make MuHV-4 LANA an 
excellent model for investigating episomal maintenance and establishment of viable 
latency in vivo. 
 
1.3.2 Modulation of cellular gene expression by mLANA 
Being obligatory intracellular parasite, MuHV-4 has evolved a repertoire of 
mechanisms to modulate specific host cellular genes to favor their own replication. 
MuHV-4 manage to do so through the activity of mLANA, which has been implicated to 
function as nuclear regulator of transcription and to interact with several cellular 
proteins to modulate host functions (Verma et al., 2007). One of such mechanisms 
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targets nuclear factor-kappa B (NF-kB), a family of ubiquitously expressed transcription 
factors. NF-kB family members can form homo- or heterodimers and bind to specific 
DNA sequences, kB sites, in the promoter region of a variety of genes to modulate their 
transcription/expression (Saccani et al., 2003). Genes regulated through NF-kB are 
involved in critical biological functions, including inflammation and apoptosis as well as 
cell proliferation and differentiation (Baldwin, 2001). Recently it has been shown that 
mLANA is capable of modulating the NF-kB signaling pathway. This mechanism 
involves the assembly of an EC5S complex mediated by an unconventional SOCS-box-
like motif (amino acid residues 199-215) present in mLANA. EC5SmLANA mimics the host 
ECSSOCS1 ubiquitin-ligase, targeting nuclear-activated RelA for poly-ubiquitination and 
subsequent proteasomal degradation, resulting in termination of NF-kB response 
(Rodrigues et al., 2009). 
Another mechanism employed by MuHV-4 to promote its own life cycle is the 
stabilization of Myc through heterotypic poly-ubiquitination (Rodrigues et al., 2013). 
MYC proto-oncogene family, which includes c-MYC, N-MYC and L-MYC, is essential 
for the control of normal cell proliferation, growth, survival and differentiation (Adhikary 
& Eilers, 2005). However, its deregulation results in an enlarge pool of proliferating, 
self-renewing cells which accelerate tumorigenesis events contributing to a wide variety 
of human cancers (Larsson & Henriksson, 2010). On the other hand, deregulation of 
MYC also triggers anti-tumorigenic responses including apoptosis, cellular senescence 
and DNA damage responses (Larsson & Henriksson, 2010). 
 Being MYC a global transcriptional regular it would be expected to be 
expressed at relatively high levels which it is not the case. MYC is tightly regulated both 
at the transcriptional and post-transcriptional levels, namely through poly-ubiquitination. 
In non-transformed cells, MYC is continuously subjected to ubiquitination and 
proteosomal-degradation, resulting in a highly unstable protein with a half-life of about 
15-20 minutes (Gregory & Hann, 2000). The mechanism involves the interplay between 
phosphorylation at two specific residues and ubiquitination. Phosphorylation at serine 
(S) 62 by extracellular signal-regulated kinase (ERK) stabilizes MYC resulting in 
enhancement of its transcription activity. In contrast, phosphorylation of MYC at 
threonine (T) 58 by glycogen synthase kinase 3 (Gsk-3), which is dependent on 
previous phosphorylation of MYC at S62, leads to proteasomal degradation of MYC 
(Sears et al., 2000). This happens because of the assembly of homotypic poly-
ubiquitination chains on MYC dependent in lysine (K) 48 linkage by SCF 
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(Skp1/Cul/Fbox)Fbw7. MYC turnover by SCFFbw7 is antagonized by polimeration of mixed 
heterotypic poly-ubiquitination chains via SCFβ-TrCP on the N-terminus of MYC (Popov et 
al., 2010).  
 Thus SCFβ-TrCP (Skp1-Cullin1-F-box) E3 ubiquitin-ligase complex mediates 
MYC poly-ubiquitination leading to its turnover and stability, instead of targeting MYC to 
proteasomal degradation (Popov et al., 2010). The physiological relevance of 
regulating MYC activity is underscored by observations that in many B-cell lymphomas, 
point mutations at or near T58 occur that disrupt phosphorylation and subsequently 
proteasomal degradation, rendering MYC resistant to degradation by SCFFbw7 (Bahram 
et al., 2000). 
It is known that MYC is essential for the initiation and maintenance of GC 
(Calado et al., 2012; Dominguez-Sola et al., 2012) and MuHV-4 depends critically on 
the expansion of latently infected B-cell in GC reactions for host colonization. GC 
reactions exhibit two distinct morphological areas which include the dark zone (DZ) 
adjacent to the T cell zone and the light zone (LZ) contiguous to the splenic marginal 
zone. It has been shown that MYC expression is restricted to clusters of B-cells that 
initiate GCs and a small fraction of LZ B-cells. Furthermore ablation of MYC expression 
or activity blocks GC formation (Calado et al., 2012; Dominguez-Sola et al., 2012). So 
by hijacking the post-translational control of MYC, mLANA increases the number of 
MuHV-4 infected B-cells in the GC. mLANA manages to do so by acting like β-TrCP 
adaptor protein, binding to MYC and promoting its poly-ubiquitination and subsequent 
stabilization. Thus, mLANA increase MYC stability through the cell cycle and 
subsequently lymphoproliferation and disease (Rodrigues et al., 2013). 
In an attempt to map the region of mLANA responsible for interaction with 
targets, a collection of mutants was generated with deletions across mLANA (S. 
Cerqueira unpublished data). Mapping was inconclusive but D2 (Δ11-20) was shown to 
increase E3 ubiquitin-ligase activity of mLANA resulting in stabilization of MYC and 
proteosomal degradation of NF-kB. 
 
1.4 MuHV-4 M2 Protein 
M2 gene is located at the left end of MuHV-4 genome, a region containing four 
MuHV-4 unique ORFs (M1-4) as well as eight viral tRNAs and thus, M2 was initially 
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classified as a latency-candidate gene on the basis of its genomic position (Virgin et al., 
1997). The M2 transcript produces a 192 amino acid-long protein (Husain et al., 1999) 
and does not have homology to any cellular or viral proteins. It has been shown to act 
as an adaptor protein that binds SH2 domains through two phosphor-tyrosine motifs 
and to SH3 domain through PxxP motifs (Pires de Miranda et al., 2008; Rodrigues et 
al., 2006). Later it was confirmed that M2 is a latency-associated gene by 
demonstrating its expression in latently infected murine B cell lymphoma line S11 and 
in splenocytes of intranasally infected wild type mice during the establishment of 
latency (Husain et al, 1999).  
M2 gene is expressed while establishment of latency in the spleen in several B 
cell subsets, namely germinal center and during infection in GC B cells (Flaño et al., 
2002; Marques et al., 2003). To further characterize the role of M2 expression in the 
overall establishment of a normal load, M2 recombinant viruses were used. Jacobi et al 
demonstrated that following intranasal infection of a recombinant virus without a 
functional expressing M2, there was no change in the acute phase of virus replication 
compared to that WT virus, but caused a severe decrease in the establishment of 
latency in the spleen and a defect in reactivation from latency (Jacoby et al., 2002). In 
2003, Macrae et al. besides corroborating the above results, showed that disruption of 
M2 did not affected the ability of the virus to reactivate from latency, that the mutation 
of M2 did not negatively affect the establishment of long-term latency and that in B 
cells, M2 protein is localized predominantly in the cytoplasm and plasma membrane 
(Macrae et al., 2003). The studies demonstrated that M2-deficient mutants replicate 
normally in tissue culture and display normal acute phase replication kinetics in vivo.  
Studies performed by our group showed that the M2 gene product is required 
for efficient colonization of splenic follicles but is dispensable for the expansion of 
latency infected GC B cells at early times post-infection (Simas et al., 2004).  An 
epitope was identified in the M2 protein (M284-92/Kd, residues GFNKLRSTL) that is 
actively recognized by CD8+ T cells from H2-Kd infected BALB/c mice and a CTL line 
capable of recognizing this epitope was able to kill S11 cells, meaning that M2 
expressing cells constitute a target for immune response during latency (Husain et al., 
1999).  Usherwood et al (2000), demonstrated that M291-99/Kd T cell response is B cell 
dependent, transient and apparently prompted by the rapid increase in latently infected 
cells around day 14 after intranasal infection. Adoptive transfer of M2-specific CD8+ T 
cells impaired the expansion of latency normally occurring in the spleen 14 days post-
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infection, supporting the idea that this latent antigen-specific immune response plays a 
role in controlling the initial “burst” of latently infected cells (Usherwood et al., 2000). 
Investigations from our group revealed that a single CD8+ T cell epitope sets the long-
term latent load (Marques et al., 2008) By mutating M2 anchor residues to alanines, 
either the phenylalanine at position 85 (vM2F85A) or the leucine at position 92 (vM2L92A), 
the generation of the H2-Kd-GFNKLRSTL-specific CD8+ T cells was prevented. The 
acute latency phenotype was reproduced but not the long-term sustained proliferation 
in GC B cells, indicating that this phenotype was due to the disruption of an epitope 
that is critical for CD8+ T cell-mediated control of latency in infected cells. Marques et 
al (2008), showed that disrupting CD8+ T cell recognition of M2 allowed more extensive 
proliferation of latently infected B cells. When M2 is not expressed, CD8+ T cells are not 
primed efficiently and cannot control the amplification of latency in GC B cells (Marques 
et al., 2008). 
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2. AIMS OF THE PROJECT 
The aim of this project was to investigate the oncogenic role of MYC modulation 
during gammaherpesvirus infection. To achieve this, recombinant MuHV-4 bearing 
mutations in mLANA that increase the modulation effect on MYC by over 10-fold were 
produced and phenotyped during infection of laboratory mice. To potentiate the 
genesis of tumor development, recombinant viruses combining the previous mutations 
with mutations in as H2-Kd-restricted T cell epitope, which was shown to induce 
persistent lymphoproliferation in germinal centres were also generated.  
The overall goal is that such study will reveal molecular pathways critical for 
virus-induced lymphoproliferation that can constitute future basis for the development 
of pharmacological targets to resolve virus-associated disease. 
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3. MATERIALS AND METHODS 
 
3.1 Plasmids 
pCMV-Myc enconding mLANA-D2 was generated by site-directed mutagenesis 
using QuickChange II XL kit (Agilent Technologies) according to the manufacturer’s 
instructions (S. Cerqueira). 
To generate pCMV-Myc-mLANA-D2-maxGFP, pCMV-Myc-maxGFP and pCMV-
Myc-mLANA-D2 were digested with EcoRI to excise maxGFP (0.7 kb) and to linearize 
the plasmid encoding mLANA-D2 (4.8 kb). The digested fragments were gel purified 
using Agarose Gel DNA Extraction Kit (Roche) according to the manufacturer’s 
instructions, and ligated. Competent E. coli DH5α were transformed by the heat shock 
method and colony PCR was performed using primers CMV F (5'-
GATCCGGTACTAGAGGAACTGAAAAAC-3') and CMV R (5'-
AATAGCATCACAAATTTC-3') to confirm ligation of the maxGFP. PCR products with 
the insert were purified using High Pure PCR Product Purification Kit (Roche) 
according to the manufacturer’s instructions. pCMV-Myc-mLANA-D2 fused with 
maxGFP was then digested with PstI to confirm the direction of maxGFP insert in the 
pCMV-Myc-mLANA-D2 (1980 bp). 
 
3.2 Bacteria  
Competent E. coli harboring BAC WT or BACL92A (Marques et al., 2003) were 
used during the generation of recombinant viruses. 
 
3.3 Mice 
BALB/c mice used in this study were obtained from Charles River. Animals 
were housed and subjected to experimental procedures in specific pathogen-free 
conditions, at the Instituto de Medicina Molecular animal facility, Lisbon, Portugal. 
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3.4 Cell culture and DNA Transfections 
NIH 3T3 – Cre (mouse embryonic fibroblasts) were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10 % foetal calf serum, 2 mM L-
glutamine and 100 U/mL penicillin-streptomycin. Cre 3T3 cells were used during the 
construction of recombinant MuHV-4 viruses to remove the loxP-flanked BAC cassette. 
Baby hamster kidney (BHK-21) fibroblasts cells were cultured in Glasgow minimum 
essential medium (GMEM) supplemented as above plus 10 % tryptose phosphate 
broth. These cells were used for growing and titrating viral stocks, ex vivo reactivation 
and plaque assays, in vitro multi-step growth curves and analysis of mLANA 
expression.  
Transiently transfection of BHK 21 cells with plasmid DNA was performed with 
X-tremeGENE HP DNA Transfection Reagent (Roche Applied Science) according to 
manufacturer’s instructions. A20 murine B lymphoma cells were cultured in RPMI 
medium supplemented with 10 % foetal calf serum, 2 mM L-glutamine and 100 U/mL 
penicillin-streptomycin. A20 cells were used for immunofluorescence. Transfection of 
A20 cells was accomplished by electroporation (270 V, 500 F), using a Bio-Rad gene 
pulser. In all transfections, an empty vector was used to normalize the total amount of 
plasmid DNA. All cell cultures were grown in a tissue culture incubator at 37 ºC under 5 
% CO2. 
 
3.5 Transformation of competent cells 
Competent E .coli DH10B harboring BAC WT or BACL92A (Marques et al., 
2003) were transformed by the heat shock method. Each aliquot was incubated on ice 
for 30 min with 1 μg of plasmid DNA (shuttle plasmid), followed by heat shock for 45 
sec at 42 ºC and subsequently chilled on ice for 2 min. 500 μL of SOC medium (2 % 
tryptone, 0.5 % yeast extract, 10 mM NaCl, 2.5 mM MgCl2, 10 mM MgSO4 and 20 mM 
glucose) were added to each vial and cells were incubated for 1 h at 30 ºC. Cells were 
then spread onto LB agar plates containing chloramphenicol (17 μg/mL) and 
kanamycin (30 μg/mL). 
Competent E. coli DH5α were transformed as above and spreaded on LB agar 
plates containing ampicillin (100 μg/mL). 
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3.6 Generation of recombinant virus 
MuHV-4 recombinant viruses were generated by mutagenesis of the viral 
genome cloned as a bacterial artificial chromosome (BAC) (Adler et al., 2000). D2 
deletion (mLANA nucleotides 11-20) was introduced by PCR on BamHI-G genomic 
clone using QuickChange II XL (Agilent Techonologies). Recombinant BamHI-G 
fragment was subcloned into the BamHI site of pST76K-SR shuttle plasmid and 
transformed into an Echerichia coli strain (DH10B) containing the wild-type MuHV-4 
BAC or MuHV-4 BACL92A (S. Cerqueira). Bacteria were plated on LB plates 
containing kanamycin (shuttle plasmid resistance marker) and chloramphenicol (BAC 
plasmid resistance marker) and incubated overnight at 30 ºC, since the shuttle plasmid 
has a temperature-sensitive origin. The shuttle plasmid encodes the recA protein that 
promotes the complete integration of the shuttle plasmid into the viral BAC genome by 
homologous recombination (Adler et al., 2003). Bacteria containing the cointegrate 
were selected by incubation overnight at 42 ºC on LB plates containing both antibiotics. 
Clones were replated on chloramphenicol-containing LB plates and grown for one day 
at 30 ºC. Under these conditions, cointegrates can spontaneously resolve by 
homologous recombination to either wild-type or mutant BAC plasmid. Bacteria 
harboring a resolved cointegrate were selected by replating on LB plates containing 
chloramphenicol and 5 % sucrose (counterselection against SacB gene encoded by 
the shuttle plasmid) and grown at 30 ºC. Colonies were plated in parallel on 
kanamycin- and chloramphenicol-containing plates and incubated overnight at 37 ºC. 
 
3.7 Small scale BAC plasmid preparations 
For small BAC plasmid preparations chloramphenicol-resistant kanamycin-
sensitive colonies were inoculated in 10 mL of LB broth containing chloramphenicol (17 
μg/mL) with shaking for 12-18h at 37 ºC. Bacteria were pelleted by centrifugation at 
1575 xg for 10 min. at 4 ºC. Pellet was resuspended in 200 µl of buffer S1 (50 mM Tris-
HCl pH 8.0, 10 mM EDTA; from Qiagen) by pipetting. 300 µl of buffer S2 (200 mM 
NaOH, 1 % SDS; from Qiagen) were added, suspension was gently mixed by inversion 
and left at RT for 5 min. 300 µl of chilled buffer S3 (3.0 M KOAc pH 5.5; from Qiagen) 
were added, tubes were inverted to mix the solution, incubated on ice for 15 min. and 
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centrifuged for 10 min at 16200 xg at 4 ºC. Supernatant was then transferred to a new 
tube, 1 ml of phenol/chloroform (1:1) was added and mixed by inversion. Mixture was 
left at RT for 5 min. BAC plasmid DNA was pellet by centrifugation for 30 min. at 16200 
xg at 4 ºC. Supernatant was discarded and the pellet was washed with 70 % ethanol, 
centrifuged another 10 min., drained and air dried. DNA was resuspended in 50 µl of 
MiliQ water and stored at 4 ºC. 
 
3.8 Identification of recombinant BAC clones 
To identify mutant BAC clones, the region containing the mutation was amplified 
by PCR with primers ORF73Rb (5'-AAAGCGGCCGCTGTCTGAGACCCTTGTCC-3') 
and CS7 (5´-AAAGAATTCTAATGCCCACATCC-3') and identified by DNA sequencing.   
Recombinant BAC clones were then isolated by large-scale BAC preparations 
using Nucleic Acid and Protein Purification kit (Macherey-Nagel), according to 
manufacturer’s instructions. Briefly, single colony bacteria were inoculated in 250 mL of 
LB broth supplemented with chloramphenicol and incubated with shaking for 12-18h at 
37 ºC. Bacteria were then pellet by centrifugation at 3214 xg for 15 min. at 4 ºC and 
BAC plasmid DNA was isolated using the above mentioned kit. DNA was then 
resuspended in 100 µl of MiliQ water and stored at 4 ºC. The integrity of recombinant 
BAC clones was confirmed by restriction digestion with BamHI and EcoRI and 
restriction profiles were assessed by agarose gel electrophoresis with 0.8 % agarose in 
1x TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.0). 
 
3.9 Reconstitution of MuHV-4 virus from BAC DNA 
For virus reconstitution, recombinant BAC DNA (1 µg) was transfected into 
BHK-21 cells (5x105) using X-tremeGENE HP DNA Transfection Reagent (Roche 
Applied Science), according to manufacturer’s instructions. When approximately 50 % 
cpe was visible, cells and media were harvested and subjected to a freeze-thawing 
cycle to disrupt the cells and stored at -80 ºC. The obtained viral aliquots constituted 
the BAC+ master stock. The loxP-flanked BAC cassette was removed by viral passage 
through NIH Cre 3T3 cells and limiting dilution to obtain GFP-negative viruses.  
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3.10 Virus working stocks 
For virus working stocks, BHK-21 cells were infected at a low MOI (0.001 
pfu/cell) in 175 cm2 culture flasks. After an incubation period of 4 days, cells and 
supernatant were transferred to 50 mL falcon and centrifuged at 290 xg, 4 ºC for 5 min. 
Cell-associated viruses were resuspended in 2 mL of complete GMEM, subjected to 
freeze-thawing and kept at -80 ºC in 200 µl aliquots. Supernatant-associated viruses 
were centrifuged at 15000 xg for 2h at 4 ºC and the pellet was resuspended in 2 mL of 
complete GMEM. 100 µl aliquots were made and store at -80 ºC. Virus titers were 
determined by plaque assay. 
 
3.11 Plaque Assay (Suspension Assay) 
Virus titers were determined by plaque assay (or suspension assay). 5x105 
BHK-21 cells were added to a serial 10-fold dilution of virus suspensions in 2 mL of 
complete GMEM and incubated for 1h. 3 mL of complete GMEM were then added and 
the suspension was plated out into 6 well-plates. After 4 days incubation at 37ºC and 5 
% CO2, cell monolayers were fixed with 10 % formaldehyde in PBS and stained with 
0.1 % toluidine blue. Viral plaques were counted using a magnifier lenses and virus 
titers were calculated from the number of viral plaques on duplicate dishes. 
 
3.12 In vitro Multi-Step Growth Curves 
Low multiplicity growth curves were performed on confluent BHK-21 cell 
monolayers in 24-well plates. BHK-21 cells (5x104 cells) were infected with the WT 
virus and mutant versions at a multiplicity of infection (MOI) of 0.01 pfu/cell, in a total 
volume of 200 µL, in each well. Virus was then allowed to adsorb for 1h at 37 ºC. Cells 
were washed with 500 µL of PBS and resuspended in 1 mL of fresh GMEM. At each 
different time point after infection, cells and supernatant were harvested, subjected to 
freeze- thawing and kept at -80 ºC. Virus titers were determined by suspension assay 
in duplicate. 
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3.14 Infectious Centre Assay 
Infectious center assay is a well-established assay in which single cell 
suspensions are prepared from the harvested spleens of infected mice and co-cultured 
with permissive fibroblasts cells. The presence of latent virus in the initial splenocyte 
population is revealed by the observation of cytopathic effects (cpe) on the above cells.  
Female BALB/c mice with 6 to 8 weeks old were inoculated intranasally with 
1x104 pfu in 20 µL of PBS with WT virus and mutant versions, under isofluorane 
anaesthesia. At days 14, 21 and 50 after infection, mice were sacrificed by inhalation of 
CO2 and spleens were dissected into 5 mL of complete GMEM and kept on ice for the 
majority of the assay. Single splenocyte suspensions were obtain by mechanical 
disruption and filtered through a 100 μm cell strainer in order to remove stromal debris. 
Cells were then pellet by centrifugation at 217 xg for 5 min. at 4 oC. Supernatant was 
discarded and cells were resuspended in 1 mL of Red Blood Cells Lysis Buffer (154 
mM ammonium chloride, 14 mM sodium hydrogen carbonate, 1 mM EDTA pH 7.3) and 
incubated on ice for 5 min. 10 mL of complete GMEM was added, cells were 
centrifuged and resuspended in 5mL of fresh medium. 2-fold and 10-fold serial dilutions 
of splenocyte suspensions were prepared, in duplicate, to a final volume of 2 mL in 12-
well plates. 5x105 BHK-21 cells in 4 mL of complete GMEM were plated in 6 cm2 dishes 
and 1 mL of each splenocyte dilution was added. Plates were incubated for 5 days at 
37 oC, 5 % CO2, and then were fixed with 1 % formaldehyde in PBS and stained with 
0.1% toluidine blue. Viral plaques were counted with the help of a magnifier lenses and 
infectious centers (pfu/spleen) were determinate in duplicate.  
In order to confirm that the results obtained for each virus was a reflection of a 
truly latent infection; spleens were also analyzed for the presence of pre-formed 
infectious centers viruses in freeze-thawed splenocyte suspensions by plaque assay.  
 
3.15 Immunofluorescence analysis  
A20 cells grown on poly-L-lysine-coated coverslips were transiently transfected 
with 15 µg of pCMV-Myc-mLANAD2-max-GFP or pCMV-Myc-mLANA-GFP. After 24 h, 
cells were washed in PBS and incubated in fixative solution (2 % sucrose and 5 % 
formaldehyde in PBS) for 20 min. After three washes in PBS, cells were permeabilised 
 17 
 
(0.1 % Triton X-100 in PBS) for 15 min, and then washed once in PBS. DNA was 
stained with DAPI solution (5 µg/mL) in order to the nucleus be visualized. Following 
staining, cells were once again fixed in fixative solution for 5 min. After three washes in 
PBS, coverslips were rinsed in distilled water and mounted onto microscope slides with 
Mowiol. 
 
3.16 Immunoblotting 
For analysis of mLANA expression, BHK-21 cells (5x105) were infected with 
MuHV-4 WT virus and recombinant virus at a MOI of 2.5 pfu/cell in a total volume of 
750 µL. Viruses were allowed to adsorb for 1h at 37 ºC and then 2 mL of complete 
GMEM was added. Cells were incubated for 24 h at 37 ºC. After 24 h, cells were 
washed in PBS, harvested and transferred to a total volume of 1 mL. Cell suspension 
was centrifuged at 16200 xg, 10 min, 4 ºC. Cell pellets were lysed with 25 µL of 
Passive Lysis Buffer (Promega). Samples were cleared by centrifugation at 3700 xg, 2 
min. at 4 ºC. 25 µL of supernatant were recovered and added to 25 µL of reducing 
Laemmli’s buffer (2x) and heated at 100 ºC for 10min. Proteins were then resolved by  
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 1.5 mm 
mini-slab gels of Bio-Rad mini-protean II electrophoresis system. Resolving gel was 
prepared with 10 % polyacrylamide (Acrylamide:bis-acrylamide 37.5:1, Bio-Rad), 375 
mM Tris-HCl (pH 8.8), 0.1 % SDS, 0.1 % APS and 0.04 % TEMED. Stacking gel was 
prepared with 4 % polyacrylamide, 125 mM Tris-HCl (pH 6.8), 0.1 % SDS, 0.1 % APS 
and 0.1 % TEMED. Electrophoresis was performed in running buffer (25 mM Tris-base, 
192 mM glycine and 0.1 % SDS), at 120 V. 
After resolved by SDS-PAGE, proteins were transferred to a nitrocellulose 
membrane using a Trans-Blot Cell (Bio-Rad), assembled according to manufacturer’s 
instructions, in a standard transfer buffer (25 mM Tris-Base, 200 mM glycine and 10 % 
methanol) for 1h 30 min at 250 mA. Following electroblotting, any unoccupied protein 
binding sites were blocked by incubation of the membrane in a 5 % (w/v) skimmed milk 
powder in PBS-T (PBS with 0.05 % Tween 20) for 1h at RT on a shaking platform. 
mLANA protein was detected with anti-mLANA monoclonal antibody (1:1000 in 
blocking buffer) (Pires de Miranda et al, 2013) with incubation for 2 h, at RT on a 
shaking platform. The membrane was washed in PBS-T three times, 5 min. each with 
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incubation in a shaking platform to remove the unbound primary antibody.  The primary 
antibody was detected by incubation of the membrane with horseradish peroxidase-
conjugated anti-mouse IgG (1:5000 in blocking buffer) for 50 min. at RT, again in a 
shaking platform. The membrane was washed as described above and the proteins 
bands were visualized by chemiluminescence using ECL according to manufacturer’s 
instructions. 
Actin was detected with a rabbit anti-actin polyclonal antibody (Sigma). 
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4. RESULTS 
 
4.1 Generation and characterization of recombinant MuHV-4 viruses 
In order to investigate the oncogenic role of MYC, two mLANA mutants were 
generated. mLANA-D2 bearing a deletion in nucleotides 11-20, which increase E3 
ubiquitin-ligase activity of mLANA, resulting in stabilization of MYC and proteosomal 
degradation of NF-kB and mLANA-D2L92A which combine the previous mutation with 
substitution of alanine by leucine at position 92 in the M2 anchor residues, using 
MuHV-4 BAC pHA3 (Adler et al., 2000). This technique allows the maintenance of the 
viral genome as a BAC in E. coli and the site-directed mutagenesis of the genome by 
homologous recombination (Adler et al., 2003). The generation and initial 
characterization of the recombinant viruses is described in detail in Materials and 
Methods. The confirmation of the integrity of the mLANA mutations was made through 
sequencing across the mutated region in the BAC plasmid. The MuHV-4 genome 
contains a number of repeats; the terminal repeats, an internal 100 bp repeat and an 
internal 40 bp repeat (Virgin et al., 1997) which may be prone to recombination events 
and although the viral BAC plasmids were maintain in recA-negative bacterial strain 
(DH10B), recombination between direct repeats may cause deletion in the copy 
number of the repeated sequences. Therefore, the stability of the viral genomes cloned 
as BAC plasmids were verified by digestion with EcoRI and BamHI and compared with 
MuHV-4 BAC (Figure 1). Identical restriction profiles indicate that no gross changes in 
genome occurred. Infectious viruses were reconstituted by transfecting the BAC-DNA 
into BHK-21 fibroblasts. The viruses were then sub-cultivated through Cre 
recombinase-expressing fibroblasts to remove the BAC vector sequences. 
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Figure 1. Stability of viral genomes cloned as BAC plasmids in E. coli. BAC plasmids were 
digested with EcoRI and BamHI restriction enzymes and restriction profiles were compared with 
ones of MuHV-4 BAC. Marker sizes (in kilobase pairs) are indicated on the left. The analysis of 
the clones is shown on a Gel Red-stained agarose gel. 
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4.2 Recombinant MuHV-4 viruses display normal growth in vitro 
The kinetics of viral replication of the recombinant viruses was assessed by a 
multisptep growth curves in permissive BHK-21 fibroblasts, infected at a MOI of 0.01 
pfu/cell. It was demonstrated that mLANA is not essential for in vitro replication of 
MuHV-4, since mLANA-negative viruses displayed normal growth (Fowler et al., 2003; 
Moorman et al., 2003). On the other hand, M2 was also demonstrated to be 
dispensable for lytic replication in vitro, studies have showed that M2-deficient mutants 
display normal acute phase replication kinetics (Jacoby et al., 2002; Macrae et al., 
2003; Simas et al., 2004).  All viruses replicated equivalently to the WT at all-time 
points measured.  
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Figure 2. Recombinant MuHV-4 viruses show normal in vitro replication. Multistep growth 
curves were constructed by infection of BHK-21 cells with the indicated virus at a multiplicity of 
infection of 0.01 pfu/cell and washed in PBS. At the indicated times post-infection, samples 
were harvested, freeze-thawed and titers were determined by plaque assay on monolayers of 
BHK-21 cells. 
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4.3 MuHV-4 LANA-D2 and LANA-D2L92A have a deficit in splenic 
latency 
In order to phenotype and analyze the effect of the introduced mutations in 
MuHV-4 latent phase of infection, BALB/c mice were infected intranasally with vWT, 
mutante versions and vM2L92A, which served as control for the M2 mutation, and the 
latent load in the spleen was examined by quantification of ex vivo reactivation-
competent viruses by infectious center assay. This assay consists of co-cultivation of 
single cells suspensions prepared from the harvested spleens with permissive 
fibroblasts cells. The presence of latent viruses in the initial splenocyte population 
results in cytopathic effect (cells lysis plaques) on fibrobaslts monolayers. Unless 
formerly infectious viruses are present at the time of harvest, the cytopathic effect (cpe) 
can only result from viral reactivation latency. The four viruses were evaluated at days 
14, 21 post-infection (pi) for their capacity of establish and expand a latent load in the 
spleen and day 50 pi for their ability to maintain a long-term persistence. The results 
are shown in Figure 3. The WT virus presented the expected peak of infection at day 
14 pi, with latent infection persisting through day 21 to become undetectable by day 50 
pi. The vM2L92A also displayed an expected pattern of infection, with the presentable 
epitope having a major impact on the long-term viral load as can be seen at day 50 pi 
(Marques et al., 2008). In contrast, both D2 and D2L92A viruses showed a major deficit 
in establishing and maintaining a latent infection, presenting approximately 3-log less 
reactivation-competent viruses than the WT virus. While D2-infected mice still 
displayed a minor latent virus load, with the latent viruses just above the limit of 
detection, the D2L92A latent viruses were below the limit of detection. During the long-
term latency, the behavior of D2 and D2L92A viruses was the total opposite of the 
M2L92A virus, meaning there were no reactivation-competent viruses at day 50 pi. 
Since the D2L92A virus has a mutation in the H2-Kd-restricted T cell epitope, it would 
be expected to induce a long-term latent load with latent virus numbers similar to 
M2L92A ones at day 50 pi. In contrast, at day 50 pi, the latent viruses were below the 
limit of detection, with no apparent long-term latency.  
To confirm that the results obtained for each virus reflected a truly latent 
infection, spleen samples were analyzed for presence of pre-formed infectious viruses. 
To do so, replicate samples were subjected to freeze-thawing, which disrupts the cells, 
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making impossible reactivation from latency but does not inactivate pre-formed viruses. 
Replicating viruses were then detected by incubation with permissive fibroblasts and 
examined for the presence of cpe. As can be seen in Figure 3, no pre-formed infectious 
viruses could be detected at any time point for any of the analyzed viruses. 
  
 
 
Figure 3. Recombinant MuHV-4 viruses display a strong latency deficit. Mice were infected 
intranasally with 1x104 pfu of the indicated viruses. At 14, 21 and 50 days post-infection, spleens 
were removed and titrated for reactivation-competent virus by explant co-culture with BHK-21 
cells. Each point represents the titer of an individual mouse. The horizontal bars show arithmetic 
means. The dashed horizontal line represents the limit of assay detection.  
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4.4 Mutation mLANA-D2 does not affect its nuclear localization 
mLANA has a putative nuclear localization signal (NLS) in residues 21 to 37 
(KRRCFNKPAAMPPKRRR) and, like kLANA, is a nuclear protein (Rodrigues et al., 
2009, Ballestas et al., 1999, Habison et al., 2012). It localizes primarily to the nucleus 
when transiently expressed in HEK 293T (Rodrigues et al., 2009). To assess if the 
introduced mutation affected the cellular localization of mLANA-D2, A20 cells were 
transiently transfected with either wtmLANA or mLANA-D2 encoding plasmids fused 
with GFP, and localization was assessed by immunofluorescence. Results showed that 
mLANA-D2, similarly to wtmLANA, localizes to the nucleus of transfected cells (Figure 
4). 
 
 
 
Figure 4. mLANA-D2 localises to the nucleus. A20 cells were transiently transfected with a 
plasmid encoding mLANA-D2-GFP (panels a,b and c) or wtmLANA-GFP (panels d,e and f). 
After 24 h, cells were incubated in fixative solution and permeabilised. Nuclear DNA was 
stained with DAPI solution (blue) to visualize the nucleus. 
 25 
 
4.5 Expression of mLANA mutants 
To further investigate if mLANA recombinant viruses were expressing the viral 
protein and that the phenotype exhibited in the infectious center assay was not due to a 
deficit in mLANA expression, BHK-21 cells were infected with WT virus and 
recombinant versions at a MOI of 2,5 pfu/cell and immunblotting was performed with 
the appropriate antibodies. Following 24 h of infection against mLANA and α-actin 
antibody, which serve as a loading control for cell infection, all four viruses expressed 
mLANA in infected fibroblasts (Figure 5). Both D2L92A and M2L92A viruses express 
mLANA equivalently, being D2 the virus less expressing the viral protein. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Expression of mLANA mutants is equivalent. BHK-21 cells were infected with WT 
MuHV-4 and recombinant versions at a MOI of 2.5 pfu/cell. After 24 h, of infection, mLANA and 
α-actin levels were analyzed by Western blotting using the indicated antibodies (first and 
second panels). Molecular weight (in kDa) is indicated on the left. 
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5. DISCUSSION  
During this project, two recombinant viruses – vD2 and vD2L92A, were 
generated in order to evaluate the oncogenic role of MYC during gammaherpesvirus 
infection. They were cloned as bacterial artificial chromosomes (BACs) since this 
technique allows the maintenance of viral genomes by a BAC in E.coli and 
mutagenesis of the virus genome using the bacterial recombination machinery (Adler et 
al., 2003). The integrity of mLANA mutations was assessed by sequencing and the 
stability of the viral genomes cloned as BAC was verified by restriction digestion and 
compared with MuHV-4 BAC. Afterwards, infectious viruses were reconstituted by 
transfecting the BAC-DNA into BHK-21 cells and were subjected to sub-cultivation 
throught Cre-recombinase-expression fibroblasts to remove the BAC vector 
sequences, since the presence of the BAC vector sequences can attenuate virus 
growth in vitro compared to the WT (Adler et al., 2001). In the MuHV-4 BAC, the BAC 
sequences are flanked by loxP sites and the expression of Cre recombinase from the 
cellular genome can efficiently excise the BAC sequences during growth.  
During the generation and characterization of recombinant viruses, revertant 
viruses should have been generated too in order to ensure that the eventual phenotype 
alterations in vD2 and vD2L92A viruses were due to desired mutations and not due to 
mutations accidentally introduced elsewhere in the viral genome. The phenotype of 
such revertants should be restored to wild type status.   
Both recombinant viruses display normal growth in vitro, having a replication 
kinetics equivalent to WT, indicating that introduced mutations did not affected lytic 
replication. The results are in agreement with former studies showing that mLANA is 
not essential for in vitro replication of MuHV-4 (Fowler et al., 2003; Moorman et al., 
2003). Likewise, M2 was also demonstrated to be dispensable for lytic replication 
(Jacoby et al., 2002; Macrae et al., 2003; Simas et al., 2004).  
Being mLANA a nuclear protein (Rodrigues et al., 2009), it has a putative 
nuclear localization signal in residues 21 to 37 and, although the mutation introduced in 
mLANA-D2 was not in the NLS, it could modify the structure of the protein and prevent 
its nuclear localization. The results showed that the introduced deletion did not affect 
the nuclear localization of mLANA-D2 as can be assessed by the immunofluorescence 
assay in transiently transfected A20 cells. 
The experiment was engineered with mLANA-D2 encoding plasmids fused with 
GFP, which, nevertheless, provides information regarding the possible disruption of 
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mLANAD2 NLS during the generation of recombinant virus. However, it would be more 
interesting to assess the nuclear localization of vD2 in the infected splenocyte 
population, using an antibody against the viral protein, mLANA. 
The recombinant viruses were able to express mLANA as it was verified by the 
immunoblotting in BHK-21 cells. There were some expression differences between the 
viruses but the overall result showed that the introduced mutations did not affected the 
in vitro protein expression and that the phenotype of the infectious center assay was 
not due to the viral protein not being expressed. For the next step it would also be 
interesting to investigate the expression of mutated mLANA in the infected splenocyte 
population as well, in order to see the expression of the viral protein in a more 
physiological context. This last step would ensure the integrity of the recombinant 
viruses. 
Since both mLANA and M2 proteins are especially required for latent infection 
during MuHV-4 pathogenesis, the recombinant viruses were analyzed in vivo. In the 
infection center assay, vD2 and vD2L92A display a major deficit in splenic latency, 
incapable of establishing and maintaining a latent infection. As complement to the ex 
vivo assay, spleen samples were analyzed for the presence of pre-formed viruses. As 
can be seen in Figure 3, pre-formed infectious virus, as measured by the parallel 
titration of equivalent frozen-thawed samples, was below the limit of detection, 
indicating that the splenic infection was solely latent. This phenotype could be the 
result of several factors. 
Being mLANA essential for episome maintenance and persistence, the D2 
mutation may have created a not functional latency protein, making it loss the episomal 
maintenance capacity.   
Moreover, since both mLANA and kLANA share an extensive similarity and homology 
in the C-terminal region (Correia et al., 2013) it is possible that the N-terminal region of 
mLANA has a histone binding property similar to kLANA (Barbera et al., 2006). The D2 
mutation could have resulted in recombinant viruses’ inaptitude to attach to host 
chromosomes, impairing the ability to maintain latency during infection. The ability of 
mLANA mutants to interact with H2A histone was tested by immunoprecipitation 
experiment, a method used to study protein-protein interactions (data not shown). The 
result was inconclusive. Further immunoprecipitation conditions must be developed in 
order to test interaction of such proteins. 
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It is known that MYC is essential for the initiation and maintenance of GC 
(Calado et al., 2012; Dominguez-Sola et al., 2012) and that MYC deregulation can lead 
to opposites effects, such as tumorigenesis events which contribute to a variety of 
human cancers and anti-tumorigenic responses, such as apoptosis (Larsson & 
Henriksson, 2010). Since D2 mutation increases E3 ubiquitin-ligase activity of mLANA 
which results in stabilization of MYC, its overexpression could have led to a mutation in 
the germinal center or to a response as apoptosis, resulting in a deficit of splenic 
latency. 
As a complement to the ex-vivo assay, limiting dilution analysis of virus-
genome-positive cells in total splenocytes combined with real-time PCR should have 
been determinated, since one can argue that plaque assay was not sensitive enough to 
detect infectious recombinant MuHV-4 viruses or that the ex-vivo assay alone does not 
permit to deduce if the deficit is in latency or in reactivation from latency. 
The assay consists of single cell suspensions obtained from pools of three 
spleens/virus which then are serially diluted 2-fold and 12 replicates of each cell 
dilutions are lysed overnight. The next day, samples are analyzed by real-time PCR 
with primer-probe sets specific for a viral protein. For each cell dilution, the number of 
negative PCR reactions, corresponding to a failure to obtain an amplification curve 
during the PCR cycles is determined. The frequency of virus DNA+ cells is then 
calculated according to the single-hit Poison Model by maximum likelihood estimation. 
This model assumes that one limiting cell of one cell subset is necessary and sufficient 
for generating a positive response.  
Since both vD2 and vD2L92A did not induced lymphoproliferation with further 
potentiating the genesis of tumor development, and could not establish a latent 
infection, a new approach must be developed to reveal molecular pathways critical for 
virus-induced lymphoproliferation. However it would also be interesting to identify 
mLANA and histones binding motifs, to shed some light in the deficit of latency. 
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6. CONCLUSION 
This project allowed the exclusion of two recombinant viruses, vD2 and vD2L92A, 
as a way to study the oncogenic role of MYC modulation during gammaherpesvirus 
infection. Mutation at mLANA N-terminal region and mutation in a H2-kd-restricted T 
cell epitope display a major deficit in splenic latency, incapable of establishing and 
maintaining a latent infection. Hence, vD2 and vD2L92A are not useful in future 
experiments and other approaches must be developed. Recombinant viruses capable 
of sustaining a latent infection must be engineer. Moreover, experiments to explore 
regions within the N-terminus of mLANA that interact with host histones must be 
exploited. Such results could help to understand the molecular pathways of Kaposi’s 
sarcoma-associated herpesvirus latency. 
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